- More than 20 abstracts, including one late-breaking
presentation, underscore AbbVie's dedication to advancing care for
dermatologic conditions
NORTH
CHICAGO, Ill., March 13,
2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today
announced it will present more than 20 abstracts, including one
late-breaking presentation during the 2023 American Academy of
Dermatology (AAD) Annual Meeting, March
17-21, in New Orleans,
Louisiana.
"The data at this year's AAD conference demonstrate AbbVie's
commitment to investing in its dermatology portfolio to further
improve outcomes for patients with immune-mediated skin
conditions," said Celine Goldberger,
M.D., vice president, head of U.S. medical affairs, AbbVie. "We
look forward to sharing new evidence that further builds upon
AbbVie's strong scientific foundation and helps to elevate the
standards of care for patients."
The oral and poster presentations from AbbVie highlight research
across the company's collective portfolio, further demonstrating
leadership in dermatology innovation. Data feature outcomes in
psoriatic disease, atopic dermatitis and hidradenitis suppurativa
to support patients living with immune-mediated skin conditions.
Notable data presentations will include:
- A late-breaking oral presentation and several poster abstracts
assessing the efficacy, durability, and safety of risankizumab in
patients with moderate to severe plaque psoriasis, including
follow-up of over 256 weeks in patients with prior biologic
treatment, as well as abstracts assessing long-term outcomes of
risankizumab in patients with active psoriatic arthritis.
- Subgroup analyses of outcomes, including skin clearance (EASI
75, vIGA 0/1) and patient-reported outcomes (pruritis, skin
symptoms, sleep and quality of life), in adults and adolescents
with atopic dermatitis from three Phase 3 trials assessing the
efficacy and safety of upadacitinib across 52 weeks.
- A Phase 2 study evaluating the efficacy and safety of
upadacitinib in moderate-to-severe hidradenitis suppurativa.
Select AbbVie abstracts at AAD 2023 are outlined below. The 2023
AAD Annual Meeting e-Posters are available here and late-breaking
sessions are available here.
Abstract
Title
|
Presentation
Details
(All Times CT)
|
Psoriasis
|
Efficacy and Safety in
Psoriasis Patients Switching to Risankizumab After
Suboptimal Response to Secukinumab or Ixekizumab After 52
Weeks
|
Late-Breaking Oral
Presentation;
Theater B;
March 18, 2023
11:40-11:50
a.m.
|
Long-Term Safety and
Efficacy of Risankizumab for the Treatment of Moderate-to-
Severe Plaque Psoriasis: Interim Analysis of Results from the
LIMMitless Open-
Label Extension Trial Up to Five Years of Follow-Up
|
Poster #43928;
Poster Center 2:
Poster with
Oral;
March 19,
2023 1:25-1:30 p.m.
|
Long-Term Real-World
Treat-to-Target Skin Clearance and Maintenance of
Response with Risankizumab in Patients with Moderate to Severe
Psoriasis from
the CorEvitas Psoriasis Registry
|
Poster
#44047
Poster Center
2
Poster with
Oral;
March 19,
2023
1:30-1:35
p.m.
|
Risankizumab Efficacy
for Moderate-to-Severe Plaque Psoriasis Over 256 Weeks
in Patients with Prior Biologic Treatments
|
Poster
#44102;
Poster Center
2; Poster with Oral; March 19,
2023 1:40-1:45 p.m.
|
Real-World Switch Rates
of Biologics and Associated Costs in Patients with
Psoriasis
|
Poster
#41279;
Poster Center
2;
Poster with
Oral; March 19, 2023 1:45-1:50
p.m.
|
Long-Term Efficacy of
Continuous Risankizumab in Psoriasis by Body Region: An
Updated Integrated Analysis from the LIMMitless Open-Label
Extension Study
|
Poster
#44022;
E-poster
|
Long-Term Improvement
in Difficult-To-Treat Areas and Quality of Life in Patients
with Psoriasis Up to 204 Weeks Post Switch from Ustekinumab To
Risankizumab
|
Poster
#44134;
E-poster
|
Psoriatic
Arthritis
|
Impact of Risankizumab
on Nail Psoriasis and Enthesitis Among Psoriatic Arthritis
Patients with High Nail Symptom Burden
|
Poster
#44094
Poster Center
2
Poster with
Oral;
March 19,
2023
1:35-1:40
p.m.
|
Improvements in
Patient-Reported Outcomes Among Patients with Resolution of
Enthesitis and/or Dactylitis: Post Hoc Analyses from the KEEPsAKE 1
and 2 Trials
of Risankizumab in Patients with Active Psoriatic
Arthritis
|
Poster
#42267;
Poster Center
2;
Poster with
Oral;
March 19,
2023 2:05-2:10 p.m.
|
Improvements in
Manifestations of Active Psoriatic Arthritis with Risankizumab
Treatment After Intolerance or Inadequate Response to Prior
Biologic Therapy:
Subgroup Analyses from the KEEPsAKE 2 Trial
|
Poster
#43944;
E-poster
|
Atopic
Dermatitis
|
Sustained Improvement
Over 52 Weeks in Patient-Reported Itch, Symptoms, and
Quality of Life with Upadacitinib in Patients with Atopic
Dermatitis: Results from
Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
|
Poster
#42262;
Poster Center
2;
Poster with
Oral; March 17, 2023 1:40-1:45
p.m.
|
Improvement in Itch,
Symptoms and Quality of Life with Upadacitinib Through
Week 16 in Adults and Adolescents with Atopic Dermatitis: results
from Phase 3
Studies (Measure Up 1, Measure Up 2 and AD Up)
|
Poster
#42065
E-poster
|
Efficacy and Safety of
Upadacitinib in Adults and Adolescents with Moderate-to-
Severe Atopic Dermatitis: Subgroup Analysis of the Measure Up 1,
Measure Up 2
and AD Up Phase 3 Clinical Trials at 52 Weeks
|
Poster
#43049;
E-poster
|
Hidradenitis
Suppurativa
|
Efficacy and Safety of
Upadacitinib in Moderate-to-Severe Hidradenitis
Suppurativa: A Phase 2, Randomized, Placebo-Controlled
Study
|
Poster
#43799;
Poster Center
2;
Poster with
Oral; March 19, 2023 1:25-1:30
p.m.
|
SKYRIZI is part of a collaboration between Boehringer Ingelheim
and AbbVie, with AbbVie leading development and commercialization
of SKYRIZI globally.
About SKYRIZI® (risankizumab-rzaa)
SKYRIZI is an interleukin-23 (IL-23) inhibitor that selectively
blocks IL-23 by binding to its p19 subunit.1 IL-23, a
cytokine involved in inflammatory processes, is thought to be
linked to a number of chronic immune-mediated diseases, including
psoriasis.1 Phase 3 trials of SKYRIZI in psoriasis,
Crohn's disease, ulcerative colitis and psoriatic arthritis
are ongoing.2-7
SKYRIZI U.S. Uses and Important Safety
Information8
SKYRIZI is a prescription medicine used to treat adults
with:
- moderate to severe plaque psoriasis who may benefit from taking
injections or pills (systemic therapy) or treatment using
ultraviolet or UV light (phototherapy).
- active psoriatic arthritis (PsA).
- moderate to severe Crohn's disease.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about
SKYRIZI® (risankizumab-rzaa)?
SKYRIZI is a prescription medicine that may cause serious
side effects, including:
Serious allergic reactions:
- Stop using SKYRIZI and get emergency medical help right away if
you get any of the following symptoms of a serious allergic
reaction:
- fainting, dizziness, feeling lightheaded
(low blood pressure)
- swelling of your face, eyelids, lips, mouth, tongue, or
throat
- trouble breathing or throat tightness
- chest tightness
- skin rash, hives
- itching
Infections:
SKYRIZI may lower the ability of your immune system to fight
infections and may increase your risk of infections. Your
healthcare provider should check you for infections and
tuberculosis (TB) before starting treatment with SKYRIZI and may
treat you for TB before you begin treatment with SKYRIZI if you
have a history of TB or have active TB. Your healthcare provider
should watch you closely for signs and symptoms of TB during and
after treatment with SKYRIZI.
- Tell your healthcare provider right away if you have an
infection or have symptoms of an infection, including:
- fever, sweats, or chills
- cough
- shortness of breath
- blood in your mucus (phlegm)
- muscle aches
- warm, red, or painful skin or sores on your body different
from your psoriasis
- weight loss
- diarrhea or stomach pain
- burning when you urinate or urinating more often than
normal
Do not use SKYRIZI if you are allergic to
risankizumab-rzaa or any of the ingredients in SKYRIZI. See the
Medication Guide or Consumer Brief Summary for a complete list of
ingredients.
Before using SKYRIZI, tell your healthcare provider about all
of your medical conditions,
including if you:
- have any of the conditions or symptoms listed in the section
"What is the most important information I should know about
SKYRIZI?"
- have an infection that does not go away or that keeps coming
back.
- have TB or have been in close contact with someone with
TB.
- have recently received or are scheduled to receive an
immunization (vaccine). Medicines that interact with the immune
system may increase your risk of getting an infection after
receiving live vaccines. You should avoid receiving live vaccines
right before, during, or right after treatment with SKYRIZI. Tell
your healthcare provider that you are taking SKYRIZI before
receiving a vaccine.
- are pregnant or plan to become pregnant. It is not known if
SKYRIZI can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if
SKYRIZI passes into your breast milk.
- become pregnant while taking SKYRIZI. You are encouraged to
enroll in the Pregnancy Registry, which is used to collect
information about the health of you and your baby. Talk to your
healthcare provider or call 1-877-302-2161 to enroll in this
registry.
Tell your healthcare provider about all the medicines you
take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements.
What are the possible side effects of SKYRIZI?
SKYRIZI may cause serious side effects. See "What is the most
important information I should know about SKYRIZI?"
Liver problems in Crohn's disease: A person with Crohn's
disease who received SKYRIZI through a vein in the arm developed
changes in liver blood tests with a rash that led to
hospitalization. Your healthcare provider will do blood tests to
check your liver before, during, and up to 12 weeks of treatment
and may stop treatment with SKYRIZI if you develop liver problems.
Tell your healthcare provider right away if you notice any of the
following symptoms: unexplained rash, nausea, vomiting, stomach
(abdominal) pain, tiredness (fatigue), loss of appetite, yellowing
of the skin and eyes (jaundice), and dark urine.
The most common side effects of SKYRIZI in people treated for
Crohn's disease include: upper respiratory infections,
headache, joint pain, stomach (abdominal) pain, injection site
reactions, low red blood cells (anemia), fever, back pain, and
urinary tract infection.
The most common side effects of SKYRIZI in people treated for
plaque psoriasis and psoriatic arthritis include: upper
respiratory infections, headache, feeling tired, injection site
reactions, and fungal skin infections.
These are not all the possible side effects of SKYRIZI. Call
your doctor for medical advice about
side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use
it.
SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a
600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or
360 mg/2.4 mL single-dose prefilled cartridge with on-body
injector.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help. Visit
AbbVie.com/myAbbVieAssist to learn more.
Please click here for Full Prescribing
Information and Medication Guide for
SKYRIZI.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a
selective JAK inhibitor that is being studied in several
immune-mediated inflammatory diseases.9 Based on
enzymatic and cellular assays, RINVOQ demonstrated greater
inhibitory potency for JAK-1 vs JAK-2, JAK-3, and
TYK-2.10 The relevance of inhibition of specific JAK
enzymes to therapeutic effectiveness and safety is not currently
known.
The use of upadacitinib in hidradenitis suppurativa is not approved
and its safety and efficacy have not been established by global
regulatory authorities. Phase 3 trials of RINVOQ in rheumatoid
arthritis, atopic dermatitis, psoriatic arthritis, axial
spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell
arteritis and Takayasu arteritis are ongoing.11-18
RINVOQ® (upadacitinib) U.S. Use and
Important Safety Information10
USES
RINVOQ is a prescription medicine used to treat:
- Adults with moderate to severe rheumatoid arthritis (RA)
when 1 or more medicines called tumor necrosis factor (TNF)
blockers have been used, and did not work well or could not be
tolerated.
- Adults with active psoriatic arthritis (PsA) when 1 or
more medicines called TNF blockers have been used, and did not work
well or could not be tolerated.
- Adults with moderate to severe ulcerative colitis (UC)
when 1 or more medicines called TNF blockers have been used, and
did not work well or could not be tolerated.
- Adults with active ankylosing spondylitis (AS) when 1 or
more medicines called TNF blockers have been used, and did not work
well or could not be tolerated.
- Adults with active non-radiographic axial spondyloarthritis
(nr-axSpA) with objective signs of inflammation when a TNF
blocker medicine has been used, and did not work well or could not
be tolerated.
It is not known if RINVOQ is safe and effective in children with
juvenile idiopathic arthritis, psoriatic arthritis, ulcerative
colitis, ankylosing spondylitis, or non-radiographic axial
spondyloarthritis.
- Adults and children 12 years of age and older with moderate
to severe eczema (atopic dermatitis [AD]) that did not respond
to previous treatment and their eczema is not well controlled with
other pills or injections, including biologic medicines, or the use
of other pills or injections is not recommended.
RINVOQ is safe and effective in children 12 years of age and
older weighing at least 88 pounds (40 kg) with atopic
dermatitis.
It is not known if RINVOQ is safe and effective in children
under 12 years of age with atopic dermatitis.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about
RINVOQ?
RINVOQ may cause serious side effects, including:
- Serious infections. RINVOQ can lower your ability to
fight infections. Serious infections have happened while taking
RINVOQ, including tuberculosis (TB) and infections caused by
bacteria, fungi, or viruses that can spread throughout the body.
Some people have died from these infections. Your healthcare
provider (HCP) should test you for TB before starting RINVOQ and
check you closely for signs and symptoms of TB during treatment
with RINVOQ. You should not start taking RINVOQ if you have any
kind of infection unless your HCP tells you it is okay. If you get
a serious infection, your HCP may stop your treatment until your
infection is controlled. You may be at higher risk of developing
shingles (herpes zoster).
- Increased risk of death in people 50 years and older who
have at least 1 heart disease (cardiovascular) risk
factor.
- Cancer and immune system problems. RINVOQ may increase
your risk of certain cancers. Lymphoma and other cancers, including
skin cancers, can happen. Current or past smokers are at higher
risk of certain cancers, including lymphoma and lung cancer. Follow
your HCP's advice about having your skin checked for skin cancer
during treatment with RINVOQ. Limit the amount of time you spend in
sunlight. Wear protective clothing when you are in the sun and use
sunscreen.
- Increased risk of major cardiovascular (CV) events, such as
heart attack, stroke, or death, in people 50 years and older who
have at least 1 heart disease (CV) risk factor, especially if you
are a current or past smoker.
- Blood clots. Blood clots in the veins of the legs or
lungs and arteries can happen with RINVOQ. This may be
life-threatening and cause death. Blood clots in the veins of the
legs and lungs have happened more often in people who are 50 years
and older and with at least 1 heart disease (CV) risk factor.
- Allergic reactions. Symptoms such as rash (hives),
trouble breathing, feeling faint or dizzy, or swelling of your
lips, tongue, or throat, that may mean you are having an allergic
reaction have been seen in people taking RINVOQ. Some of these
reactions were serious. If any of these symptoms occur during
treatment with RINVOQ, stop taking RINVOQ and get emergency medical
help right away.
- Tears in the stomach or intestines and changes in certain
laboratory tests. Your HCP should do blood tests before you
start taking RINVOQ and while you take it. Your HCP may stop your
RINVOQ treatment for a period of time if needed because of changes
in these blood test results.
Do not take RINVOQ if you are allergic to upadacitinib or any
of the ingredients in RINVOQ. See the Medication Guide or
Consumer Brief Summary for a complete list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
- Are being treated for an infection, have an infection that
won't go away or keeps coming back, or have symptoms of an
infection, such as:
|
|
|
|
|
|
|
|
-
Fever, sweating, or chills
-
Shortness of breath
-
Warm, red, or painful skin or sores on
your body
|
-
Muscle aches
-
Feeling tired
-
Blood in phlegm
-
Diarrhea or stomach
pain
|
-
Cough
-
Weight loss
-
Burning when urinating or urinating more
often than normal
|
- Have TB or have been in close contact with someone with
TB.
- Are a current or past smoker.
- Have had a heart attack, other heart problems, or stroke.
- Have or have had any type of cancer, hepatitis B or C, shingles
(herpes zoster), blood clots in the veins of your legs or lungs,
diverticulitis (inflammation in parts of the large intestine), or
ulcers in your stomach or intestines.
- Have other medical conditions, including liver problems, low
blood cell counts, diabetes, chronic lung disease, HIV, or a weak
immune system.
- Live, have lived, or have traveled to parts of the country,
such as the Ohio and Mississippi
River valleys and the Southwest, that increase your risk of getting
certain kinds of fungal infections. If you are unsure if you've
been to these types of areas, ask your HCP.
- Have recently received or are scheduled to receive a vaccine.
People who take RINVOQ should not receive live vaccines.
- Are pregnant or plan to become pregnant. Based on animal
studies, RINVOQ may harm your unborn baby. Your HCP will check
whether or not you are pregnant before you start RINVOQ. You should
use effective birth control (contraception) to avoid becoming
pregnant during treatment with RINVOQ and for 4 weeks after your
last dose.
- Are breastfeeding or plan to breastfeed. RINVOQ may pass into
your breast milk. Do not breastfeed during treatment with RINVOQ
and for 6 days after your last dose.
Tell your HCP about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal
supplements. RINVOQ and other medicines may affect each other,
causing side effects.
Especially tell your HCP if you take:
- Medicines for fungal or bacterial infections
- Rifampicin or phenytoin
- Medicines that affect your immune system
If you are not sure if you are taking any of these medicines,
ask your HCP or pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with
RINVOQ as it may increase the risk of side effects.
What should I do or tell my HCP AFTER starting
RINVOQ?
- Tell your HCP right away if you have any symptoms of an
infection. RINVOQ can make you more likely to get infections or
make any infections you have worse.
- Get emergency help right away if you have any symptoms of a
heart attack or stroke while taking RINVOQ, including:
- Discomfort in the center of your chest
that lasts for more than a few minutes or that goes away and comes
back
- Severe tightness, pain, pressure, or heaviness in your
chest, throat, neck, or jaw
- Pain or discomfort in your arms, back, neck, jaw, or
stomach
- Shortness of breath with or without chest discomfort
- Breaking out in a cold sweat
- Nausea or vomiting
- Feeling lightheaded
- Weakness in one part or on one side of your body
- Slurred speech
- Tell your HCP right away if you have any signs or symptoms of
blood clots during treatment with RINVOQ, including:
|
|
|
|
|
|
|
|
|
|
-
Swelling
-
Pain or tenderness in one or both
legs
|
-
Sudden unexplained chest or upper back
pain
-
Shortness of breath or difficulty
breathing
|
- Tell your HCP right away if you have a fever or stomach-area
pain that does not go away, and a change in your bowel habits.
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections
(common cold, sinus infections), shingles (herpes zoster), herpes
simplex virus infections (including cold sores), bronchitis,
nausea, cough, fever, acne, headache, increased blood levels of
creatine phosphokinase, allergic reactions, inflammation of hair
follicles, stomach-area (abdominal) pain, increased weight, flu,
tiredness, lower number of certain types of white blood cells
(neutropenia, lymphopenia), muscle pain, flu-like illness, rash,
increased blood cholesterol levels, and increased liver enzyme
levels.
A separation or tear to the lining of the back part of the eye
(retinal detachment) has happened in people with atopic dermatitis
treated with RINVOQ. Call your HCP right away if you have any
sudden changes in your vision during treatment with RINVOQ.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ?
RINVOQ is taken once a day with or without food. Do not split,
crush, or chew the tablet. Take RINVOQ exactly as your HCP tells
you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg
extended-release tablets.
This is the most important information to know about RINVOQ.
For more information, talk to your HCP.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help. Visit
AbbVie.com/myAbbVieAssist to learn more.
Please click here for the Full Prescribing
Information and Medication Guide for
RINVOQ.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines that solve serious health issues today
and address the medical challenges of tomorrow. We strive to have a
remarkable impact on people's lives across several key therapeutic
areas: immunology, oncology, neuroscience, eye care, virology,
women's health and gastroenterology, in addition to products and
services across its Allergan Aesthetics portfolio. For more
information about AbbVie, please visit us at www.abbvie.com.
Follow @abbvie on
Twitter, Facebook, LinkedIn or Instagram.
AbbVie Forward-Looking Statements
Some statements
in this news release are, or may be considered, forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995. The words "believe," "expect," "anticipate," "project"
and similar expressions, among others, generally identify
forward-looking statements. AbbVie cautions that these
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
indicated in the forward-looking statements. Such risks and
uncertainties include, but are not limited to, failure to realize
the expected benefits from AbbVie's acquisition of Allergan plc
("Allergan"), failure to promptly and effectively integrate
Allergan's businesses, competition from other products, challenges
to intellectual property, difficulties inherent in the research and
development process, adverse litigation or government action,
changes to laws and regulations applicable to our industry and the
impact of public health outbreaks, epidemics or pandemics, such as
COVID-19. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2021 Annual Report on Form 10-K, which has
been filed with the Securities and Exchange Commission, as updated
by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes
no obligation to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
References:
- Duvallet E., Sererano L., Assier E., et al. Interleukin-23: a
key cytokine in inflammatory diseases. Ann Med. 2011. Nov
43(7):503-11.
- A Study on the long-term efficacy and safety of risankizumab
for the treatment of moderate-to-severe plaque psoriasis.
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT03047395. Accessed on
February 17, 2023.
- A Study of the Efficacy and Safety of Risankizumab in
Participants With Moderately to Severely Active Crohn's Disease.
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT03105128. Accessed on
March 8, 2022.
- A Study to Assess the Efficacy and Safety of Risankizumab in
Participants With Ulcerative Colitis. ClinicalTrials.gov. 2021.
Available at: https://clinicaltrials.gov/ct2/show/NCT03398135.
Accessed on March 8, 2022.
- A Multicenter, Randomized, Double-Blind, Placebo Controlled
Induction Study to Evaluate the Efficacy and Safety of Risankizumab
in Participants With Moderately to Severely Active Ulcerative
Colitis. Available at:
https://clinicaltrials.gov/ct2/show/NCT03398148. Accessed on
March 8, 2022.
- BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients
With Active Psoriatic Arthritis. Available at:
https://clinicaltrials.gov/ct2/show/NCT03675308. Accessed on
March 8, 2022.
- BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients
With Active Psoriatic Arthritis. Available at:
https://clinicaltrials.gov/ct2/show/NCT03671148. Accessed on
March 8, 2022.
- SKYRIZI (risankizumab) [Package Insert]. North Chicago, Ill.: AbbVie Inc.
- Pipeline – Our Science | AbbVie. AbbVie. 2019. Available at:
https://www.abbvie.com/our-science/pipeline.html. Accessed on
March 8, 2022.
- RINVOQ (upadacitinib) [Package Insert]. North Chicago, Ill.: AbbVie Inc.
- A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults
With Rheumatoid Arthritis on a Stable Dose of Conventional
Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have
an Inadequate Response to csDMARDs Alone (SELECT-NEXT).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT02675426. Accessed on
March 8, 2022.
- Evaluation of Upadacitinib in Adolescent and Adult Patients
With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT03569293. Accessed on
March 8, 2022.
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to
Adalimumab in Participants With Psoriatic Arthritis Who Have an
Inadequate Response to at Least One Non-Biologic Disease Modifying
Anti-Rheumatic Drug (SELECT - PsA 1). ClinicalTrials.gov. 2021.
Available at: https://clinicaltrials.gov/ct2/show/NCT03104400.
Accessed on March 8, 2022.
- A Study to Evaluate Efficacy and Safety of Upadacitinib in
Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT04169373. Accessed on
March 8, 2022.
- A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in
Participants With Moderately to Severely Active Crohn's Disease Who
Have Inadequately Responded to or Are Intolerant to Biologic
Therapy. ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT03345836. Accessed on
Accessed on March 8, 2022.
- A Study to Evaluate the Safety and Efficacy of Upadacitinib
(ABT-494) for Induction and Maintenance Therapy in Participants
With Moderately to Severely Active Ulcerative Colitis (UC).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT02819635. Accessed on
March 8, 2022.
- A Study to Evaluate the Safety and Efficacy of Upadacitinib in
Participants With Giant Cell Arteritis (SELECT-GCA).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT03725202. Accessed on
March 8, 2022.
- A Study to Evaluate the Efficacy and Safety of Upadacitinib in
Subjects With Takayasu Arteritis (TAK) (SELECT-TAK).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT04161898. Accessed on
March 8, 2022.
US-MULT-230266
View original
content:https://www.prnewswire.com/news-releases/abbvie-showcases-strength-of-dermatology-portfolio-with-new-data-presented-at-the-2023-aad-annual-meeting-301769621.html
SOURCE AbbVie